Abstract
This chapter describes the current knowledge on gonadotropin-releasing hormone agonists (GnRHa) in fertility preservation. Numerous studies are now available and have formed the basis of meta-analyses in the recent years. There is currently no molecular explanation for the effective action of GnRHa in the preservation of fertility. However, evidence from animal models suggests that the chemotherapeutic agent with which GnRHa is combined could be crucial to its preserving effect. According to current knowledge, the use of GnRHa significantly reduces the rate of premature ovarian failure. It may also have a positive effect on fertility. At present, there is no evidence to support the suspicion that GnRHa reduces the efficacy and safety of chemotherapy in hormone receptor–positive cancer. Efficacy and safety of GnRHa in fertility preservation need to be definitively elucidated in further investigations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Xu M, Pavone ME, Woodruff T. Fruitful progress to fertility: preserving oocytes from chemodestruction. Nat Med. 2011;17:1562–3. https://doi.org/10.1038/nm.2595.
Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77. https://doi.org/10.1016/j.ctrv.2018.
von Wolff M, Kämmerer U, Kollmann Z, Santi A, Dietl J, Frambach T. Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up. Fertil Steril. 2011;95:452–4. https://doi.org/10.1016/j.fertnstert.2010.08.053.
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–18. https://doi.org/10.1056/NEJMoa1404037.
Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D’Alonzo A, Canavese G, Pronzato P, Bruzzi P. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40:675–83. https://doi.org/10.1016/j.ctrv.2013.12.001.
Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36:1981–90. https://doi.org/10.1200/JCO.2018.78.0858.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS, POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–32. https://doi.org/10.1056/NEJMoa1413204.
Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:65–73. https://doi.org/10.1001/jamaoncol.2015.3251.
Hickman LC, Llarena NC, Valentine LN, Liu X, Falcone T. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. J Assist Reprod Genet. 2018;35:571–81. https://doi.org/10.1007/s10815-018-1128-2.
Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126:187–95. https://doi.org/10.1097/AOG.0000000000000905.
Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2014;102:808–15.e1. https://doi.org/10.1016/j.fertnstert.2014.06.003.
Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final analysis of the prevention of Early Menopause Study (POEMS)/SWOG intergroup S0230. J Natl Cancer Inst. 2019;111:210–3. https://doi.org/10.1093/jnci/djy185.
Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO), Kommission Mamma 2020. https://www.ago-online.de/fileadmin/agoonline/downloads/_leitlinien/kommission_mamma/2020/Alle_aktuellen_Empfehlungen_2020.pdf.
Chen H, Xiao L, Li J, Cui L, Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2019;3:CD008018. https://doi.org/10.1002/14651858.CD008018.pub3.
Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34:2568–74. https://doi.org/10.1200/JCO.2015.65.8864.
Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L, GIM Study Group. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314:2632–40. https://doi.org/10.1001/jama.2015.17291.
Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017;28:2225–32. https://doi.org/10.1093/annonc/mdx285.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nawroth, F. (2020). GnRH Agonists. In: von Wolff, M., Nawroth, F. (eds) Fertility Preservation in Oncological and Non-Oncological Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-47568-0_24
Download citation
DOI: https://doi.org/10.1007/978-3-030-47568-0_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-47567-3
Online ISBN: 978-3-030-47568-0
eBook Packages: MedicineMedicine (R0)